LARRY FLOWERS: Open Payments
NPI 1750336707 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,522 in 56 payments from 11 companies in 2025. Trend: 2023 $599 · 2024 $595 · 2025 $1,522
Food & beverage: $1,522
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 21 | $555 |
| E.R. Squibb & Sons, L.L.C. | 4 | $250 |
| Neurocrine BioSciences, Inc. | 10 | $220 |
| Alkermes, Inc. | 6 | $147 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $111 |
| ABBVIE INC. | 3 | $82 |
| Otsuka America Pharmaceutical, Inc. | 2 | $52 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| HARMONY BIOSCIENCES LLC | 1 | $26 |
| Validus Pharmaceuticals LLC | 1 | $23 |
Products named: UZEDY, COBENFY, INGREZZA, ARISTADA, CAPLYTA, VRAYLAR, INVEGA SUSTENNA, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
